HM15136 — catalyst calendar
Upcoming
| Date | Event | Company | Drug | Official source & verification |
|---|---|---|---|---|
| 2026-07 (month) in 9d
ESTIMATED |
READOUT
HM15136 (Efpegerglucagon) Treatment for 8 Weeks in Subjects Aged ≥2 Years With C
Phase 2 · Congenital Hyperinsulinism |
Hanmi Pharmaceutical Company Limit | HM15136 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-06-22
Sponsor-projected date — can change
|